Integrated
Annual Report
- Home
- DSM at a glance
- Key data for 2010
- Key data
- Letter from the Chairman
- DSM in motion: driving focused growth
- Report by the Managing Board
- Review of business
- Corporate governance and risk management
- Report by the Supervisory Board
- Supervisory Board and Managing Board
- What still went wrong
- Information about the DSM share
- Consolidated financial statements
- Financial statements of Royal DSM N.V.
- Other information
- DSM figures: five-year summary
- Sustainability reporting approach
- Explanation of some concepts and ratios
- Downloads
Review of business
In 2010 DSM's activities were grouped into four clusters: Nutrition, Pharma, Performance Materials and Polymer Intermediates.
Net sales, continuing operations
|
x € million
|
2010
|
2009
|
|
Nutrition
|
3,005
|
2,824
|
|
Pharma
|
739
|
721
|
|
Performance Materials
|
2,507
|
1,823
|
|
Polymer Intermediates
|
1,398
|
849
|
|
Other activities
|
527
|
508
|
|
Total
|
8,176
|
6,725
|
Operating profit plus depreciation and amortization (EBITDA), continuing operations
|
x € million
|
2010
|
2009
|
|
Nutrition
|
702
|
655
|
|
Pharma
|
65
|
91
|
|
Performance Materials
|
299
|
174
|
|
Polymer Intermediates
|
229
|
36
|
|
Other activities
|
(134)
|
(122)
|
|
Total
|
1,161
|
834
|
EBITDA / net sales, continuing operations
|
in %
|
2010
|
2009
|
|
Nutrition
|
23.4
|
23.2
|
|
Pharma
|
8.8
|
12.6
|
|
Performance Materials
|
11.9
|
9.5
|
|
Polymer Intermediates
|
16.4
|
4.2
|
|
Total
|
14.2
|
12.4
|
Operating profit (EBIT), continuing operations
|
x € million
|
2010
|
2009
|
|
Nutrition
|
569
|
521
|
|
Pharma
|
7
|
32
|
|
Performance Materials
|
179
|
68
|
|
Polymer Intermediates
|
192
|
6
|
|
Other activities
|
(195)
|
(194)
|
|
Total
|
752
|
433
|
Capital employed at 31 December
|
x € million
|
2010
|
2009
|
|
Nutrition
|
1,981
|
1,802
|
|
Pharma
|
907
|
789
|
|
Performance Materials
|
1,660
|
1,641
|
|
Polymer Intermediates
|
375
|
369
|
|
Other activities
|
356
|
387
|
|
Total continuing operations
|
5,279
|
4,988
|
|
Discontinued operations
|
189
|
685
|
|
Total DSM
|
5,468
|
5,673
|
Capital expenditure and acquisitions
|
x € million
|
2010
|
2009
|
|
Nutrition
|
153
|
82
|
|
Pharma
|
76
|
63
|
|
Performance Materials
|
118
|
139
|
|
Polymer Intermediates
|
46
|
25
|
|
Other activities
|
58
|
80
|
|
Total continuing operations
|
451
|
389
|
|
Discontinued operations
|
25
|
78
|
|
Total DSM
|
476
|
467
|
R&D expenditure (including associated IP expenditure), continuing operations
|
x € million
|
as % of net sales
|
|||
|
2010
|
2009
|
2010
|
2009
|
|
|
Nutrition
|
176
|
144
|
5.9
|
5.1
|
|
Pharma
|
69
|
73
|
9.3
|
10.1
|
|
Performance Materials
|
146
|
138
|
5.8
|
7.6
|
|
Polymer Intermediates
|
15
|
13
|
1.0
|
1.5
|
|
Other activities
|
18
|
10
|
3.5
|
2.0
|
|
Total
|
424
|
378
|
5.2
|
5.6
|
Workforce at 31 December
|
(headcount)
|
2010
|
2009
|
|
Nutrition
|
7,409
|
7,110
|
|
Pharma
|
4,079
|
4,374
|
|
Performance Materials
|
4,918
|
4,633
|
|
Polymer Intermediates
|
1,361
|
1,321
|
|
Other activities
|
3,726
|
3,620
|
|
Total continuing operations
|
21,493
|
21,058
|
|
Discontinued operations
|
418
|
1,680
|
|
Total DSM
|
21,911
|
22,738
|